NO20054494L - Peptidvektorer - Google Patents

Peptidvektorer

Info

Publication number
NO20054494L
NO20054494L NO20054494A NO20054494A NO20054494L NO 20054494 L NO20054494 L NO 20054494L NO 20054494 A NO20054494 A NO 20054494A NO 20054494 A NO20054494 A NO 20054494A NO 20054494 L NO20054494 L NO 20054494L
Authority
NO
Norway
Prior art keywords
peptidvektorer
neoplasia
treatment
conditions
methods
Prior art date
Application number
NO20054494A
Other languages
English (en)
Other versions
NO20054494D0 (no
Inventor
Sun H Kim
Zheng Xin Dong
Yeelana Shen
Jeanne Mary Comstock
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of NO20054494D0 publication Critical patent/NO20054494D0/no
Publication of NO20054494L publication Critical patent/NO20054494L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Det beskrives målrettede cytotoksiske forbindelser og fremgangsmåter vedrørende deres terapeutiske anvendelse for behandling av neoplasi og andre tilstander.
NO20054494A 2003-04-22 2005-09-28 Peptidvektorer NO20054494L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46452803P 2003-04-22 2003-04-22
PCT/US2004/012200 WO2004093807A2 (en) 2003-04-22 2004-04-21 Somatostatin vectors

Publications (2)

Publication Number Publication Date
NO20054494D0 NO20054494D0 (no) 2005-09-28
NO20054494L true NO20054494L (no) 2006-01-09

Family

ID=33310909

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054494A NO20054494L (no) 2003-04-22 2005-09-28 Peptidvektorer

Country Status (14)

Country Link
US (1) US8709998B2 (no)
EP (3) EP1624884A4 (no)
JP (2) JP4578470B2 (no)
KR (2) KR100817232B1 (no)
CN (2) CN101791409A (no)
AU (1) AU2004232314B2 (no)
CA (1) CA2523197C (no)
IL (1) IL171204A (no)
MX (1) MXPA05011233A (no)
NO (1) NO20054494L (no)
NZ (2) NZ576739A (no)
RU (1) RU2361876C2 (no)
SG (1) SG173223A1 (no)
WO (1) WO2004093807A2 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101791409A (zh) * 2003-04-22 2010-08-04 研究及应用科学协会股份有限公司 肽载体
CN101563360A (zh) * 2006-10-20 2009-10-21 益普生制药两合公司 肽-细胞毒性缀合物
US8236762B2 (en) * 2006-10-20 2012-08-07 Ipsen Pharma S.A.S. Peptide-cytotoxic conjugates
CN103804472B (zh) * 2014-01-23 2016-06-08 浙江大学 一种紫杉烷类药物前体
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
KR102062025B1 (ko) * 2014-06-30 2020-01-03 타베다 세라퓨틱스, 인코포레이티드 표적화된 콘주게이트 및 입자 및 그것의 제형
AU2016343817B2 (en) 2015-10-28 2021-05-27 Tva (Abc), Llc SSTR-targeted conjugates and particles and formulations thereof
WO2019115611A1 (en) * 2017-12-12 2019-06-20 Universität Leipzig Peptidic bb2 receptor agonist – saccharide functionalised carbaborane conjugates
CN109999202B (zh) * 2019-01-18 2022-03-22 南阳师范学院 一种介导紫杉醇递送的多功能肽及其应用
KR20220008869A (ko) 2019-05-14 2022-01-21 누베이션 바이오 인크. 항암 핵 호르몬 수용체-표적화 화합물
WO2021087372A1 (en) * 2019-10-31 2021-05-06 Worcester Polytechnic Institute Lhrh-paclitaxel conjugates and methods of use
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291022A (en) 1975-03-11 1981-09-22 Sandoz Ltd. Organic compounds
US4133782A (en) 1976-06-07 1979-01-09 The Salk Institute For Biological Studies Somatostatin analogs with dissociated biological activities
US4190575A (en) 1977-12-27 1980-02-26 American Home Products Corporation Polypeptides related to somatostatin
IT1105131B (it) 1977-06-08 1985-10-28 Merck & Co Inc Peptidi analoghi della somatostatina dotati di piu' lunga e maggiore attivita' biologica e relativo procedimento di protezione
US4211693A (en) 1977-09-20 1980-07-08 The Salk Institute For Biological Studies Peptides with para-substituted phenylalanine
LU78191A1 (de) 1977-09-28 1979-05-25 Ciba Geigy Ag Verfahren zur herstellung von neuen cyclopeptiden
CA1107273A (en) 1978-05-19 1981-08-18 Chester A. Meyers Somatostatin analogs having a substituted tryptophyl residue in position eight
JPS5819669B2 (ja) 1978-10-28 1983-04-19 白井松新薬株式会社 新規生理活性ペプチド化合物及びその製造法
US4215039A (en) 1979-02-15 1980-07-29 American Home Products Corporation Somatostatin analogues
US4190648A (en) 1979-03-13 1980-02-26 Merck & Co., Inc. Peptides having somatostatin activity
US4316890A (en) 1979-03-16 1982-02-23 Ciba-Geigy Corporation Peptides and processes for the manufacture thereof
US4209426A (en) 1979-05-29 1980-06-24 American Home Products Corporation Polypeptides related to somatostatin
US4431635A (en) 1979-06-13 1984-02-14 Coy David Howard LH-RH Antagonists
US4317815A (en) 1979-06-13 1982-03-02 Coy David Howard LH-RH Antagonists
US4328214A (en) 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
US4310518A (en) 1979-10-31 1982-01-12 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4235886A (en) 1979-10-31 1980-11-25 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
DE19375086I2 (de) 1979-11-27 2003-01-09 Novartis Ag Polypeptide Verfahren zu ihrer Herstellung pharmazeutische Zusammensetzungen die diese Polypeptide enthalten und ihre Verwendung
US4369179A (en) 1979-12-14 1983-01-18 Ciba-Geigy Corporation Acylpeptides
US4358439A (en) 1979-12-21 1982-11-09 Ciba-Geigy Corporation Cyclooctapeptides
US4282143A (en) 1980-06-13 1981-08-04 American Home Products Corporation Octapeptides lowering growth hormone
DK81082A (da) 1981-03-06 1982-09-07 Sandoz Ag Fremgangsmaade til fremstilling af polypeptider
US4360516A (en) 1981-04-13 1982-11-23 Merck & Co., Inc. Modified D-retro cyclic hexapeptide somatostatin analogs
AU9102582A (en) 1981-12-10 1983-06-16 David Howard Coy Lh-rh antagonists
ATE14226T1 (de) 1981-12-24 1985-07-15 Ciba Geigy Ag Cyclische octapeptide und pharmazeutische praeparate davon, sowie verfahren zur herstellung derselben und ihre anwendung.
FR2522655B1 (fr) 1982-03-05 1987-03-06 Sanofi Sa Analogues de la somatostatine possedant une liaison du type hydrazide et medicaments en contenant
US4581169A (en) 1982-12-21 1986-04-08 Syntex (U.S.A.) Inc. Nona-peptide and deca-peptide analogs of LHRH, useful as LHRH antagonists
US4486415A (en) 1983-08-15 1984-12-04 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
DE3467173D1 (en) 1983-08-16 1987-12-10 Akzo Nv Lh- rh antagonists
US4485101A (en) 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
US4522813A (en) 1983-10-27 1985-06-11 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US5075224A (en) 1984-10-19 1991-12-24 Genentech, Inc. Prepro-LHRH C-terminal peptide DNA
HUT42101A (en) 1985-01-07 1987-06-29 Sandoz Ag Process for preparing stomatostatine derivatives and pharmaceutical compositions containing such compounds
US4650787A (en) 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
US4725577A (en) 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US4642332A (en) 1985-04-26 1987-02-10 The Board Of Regents, The University Of Texas System Effective hormonal peptides: D-3-Pal6 -LHRH
US4656247A (en) 1985-04-26 1987-04-07 Board Of Regents, The University Of Texas System Effective hormonal peptides: D-3-QA1 6-LHRH
US4585755A (en) 1985-04-29 1986-04-29 Merck & Co., Inc. Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US4721775A (en) 1985-08-26 1988-01-26 Board Of Regents, The University Of Texas System Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
US4904642A (en) 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4853371A (en) 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4871717A (en) 1987-01-07 1989-10-03 Administrators Of The Tulane Educational Fund Peptides
JP2795449B2 (ja) 1987-09-24 1998-09-10 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ペプチド
US5084555A (en) 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
US5723578A (en) 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
US5877277A (en) 1987-09-24 1999-03-02 Biomeasure, Inc. Octapeptide bombesin analogs
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5140009A (en) 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
JP2673025B2 (ja) 1988-02-10 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド 小さいサイズのｌｈｒｈ類似体
GB8808768D0 (en) 1988-04-14 1988-05-18 Erba Carlo Spa Peptide ligands for bombesin receptors
GR1000608B (el) 1988-07-21 1992-08-31 Erba Carlo Spa Μεθοδος για την παρασκευη ανταγωνιστων bombesin.
DK375789A (da) 1988-08-18 1990-02-19 Syntex Inc Peptidderivater
AU638423B2 (en) 1988-10-14 1993-07-01 The Administrators Of The Tulane Eductional Fund Therapeutic peptides
CA2012115C (en) 1989-03-15 2001-07-03 Biomeasure, Inc. Iodinated somatostatins
NL8900726A (nl) 1989-03-23 1990-10-16 Stichting Centr Diergeneeskund Peptide, immunogene samenstelling en vaccin- of geneesmiddelpreparaat; werkwijze voor het immuniseren van een zoogdier tegen lhrh, en werkwijze voor het verbeteren van de vleeskwaliteit van varkens.
US5484592A (en) 1989-03-23 1996-01-16 Stitching Centraal Diergeneeskundig Instituut Peptide, immunogenic composition and vaccine or medicinal preparation: a method of immunising a mammal against LHRH, and a method of improving the meat quality of pigs
KR0173119B1 (ko) 1989-04-26 1999-02-01 닐 에이. 밴스로우 선형 소마토스타틴 유사체
CA2016584C (en) 1989-05-17 1999-06-29 Robert S. Greenfield Anthracycline conjugates having a novel linker and methods for their production
GB8913844D0 (en) 1989-06-15 1989-08-02 Erba Carlo Spa Irreversible bombesin antagonists
US5217955A (en) 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
JPH04502629A (ja) 1989-11-06 1992-05-14 フアルミタリア・カルロ・エルバ・エツセ・エルレ・エルレ 還元不可逆性ボンベシンアンタゴニスト
CA2030212A1 (en) 1989-11-22 1991-05-23 Judson V. Edwards Peptides
EP0457888B1 (en) 1989-12-08 1996-07-10 The Administrators of The Tulane Educational Fund Octapeptide analogs of somatostatin having threonine at the sixth position
ATE124054T1 (de) * 1990-04-06 1995-07-15 Univ Tulane Somatostatinanaloge.
DE69112684T2 (de) 1990-04-06 1996-02-01 Univ Tulane LHRH-Analoge.
EP0531342A1 (en) 1990-05-09 1993-03-17 The Administrators Of The Tulane Educational Fund Cyclized and linear therapeutic peptides
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
ZA915740B (en) 1990-07-26 1992-05-27 Merrell Dow Pharma Peptides
US5369094A (en) 1990-11-29 1994-11-29 The Administrators Of The Tulane Educational Fund Polypeptide bombesin antagonists
HU207104B (en) 1991-01-25 1993-03-01 Biosignal Kutato Fejlesztoe Kf Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds
PL296623A1 (en) 1991-03-01 1993-09-20 Rhone Merieux Method of improving organoleptic properties of male slaughter animal meat
US5436137A (en) 1992-07-27 1995-07-25 Oregon Regional Primate Research Center DNA sequence which encodes a peptide capable of promoting acrosome reaction
JP3568952B2 (ja) 1992-12-18 2004-09-22 アボット・ラボラトリーズ ５位及び６位に修飾アミノアシル残基を有するｌｈｒｈ拮抗薬
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
EP0708656B1 (en) 1993-04-27 2002-07-31 United Biomedical, Inc. Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
CA2123144A1 (en) 1993-05-10 1994-11-11 David Bodmer Stabilisation of pharmacologically active compounds in sustained release compositions
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5620955A (en) 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
US5410018A (en) 1994-02-25 1995-04-25 Oregon Regional Primate Research Center Bombesin-related peptides
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
AU710778B2 (en) 1995-06-07 1999-09-30 Pepscan Systems B.V. An improved peptide, immunogenic composition and vaccine or medical preparation, a method to immunise animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine
USRE39048E1 (en) 1995-06-07 2006-03-28 Pepscan Systems B.V. Peptide, immunogenic composition and vaccine or medical preparation, a method to immunise animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine
GB9513121D0 (en) * 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
KR0144618B1 (ko) * 1995-09-29 1998-07-15 김완섭 음식물 쓰레기 처리방법
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
US7078413B2 (en) 1996-04-19 2006-07-18 Wisconsin Alumni Research Foundation Compositions and methods of use for a bombesin peptide
JP2000510119A (ja) * 1996-05-03 2000-08-08 イムノメディクス，インコーポレイテッド ガンに対する標的コンビネーション免疫療法
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6156725A (en) 1996-08-16 2000-12-05 National Institute Of Immunology Drug for the treatment of cancer
EP0925506A1 (en) 1996-08-23 1999-06-30 Patel, Cell & Receptor Technologies Inc. Agonist-dependent internalization of human somatostatin receptors types 1-5
EP0835662B1 (en) 1996-10-08 2001-11-14 National Institute of Immunology A drug for the treatment of cancer
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6063796A (en) 1997-04-04 2000-05-16 Merck & Co., Inc. Somatostatin agonists
US7060247B2 (en) * 1997-04-22 2006-06-13 The Curators Of The University Of Missouri Gastrin receptor-avid peptide conjugates
US20020115596A1 (en) * 1997-10-27 2002-08-22 Merk & Co., Inc. Conjugates useful in the treatment of prostate cancer
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
CA2334809A1 (en) * 1998-06-05 1999-12-09 Board Of Regents, The University Of Texas System Texaphyrin conjugates and uses thereof
US6025468A (en) 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
GB2343182A (en) 1998-10-27 2000-05-03 Ferring Bv Use of GnRH-II and analogues thereof for the treatment of osteoporosis
WO2000050059A1 (en) * 1999-02-24 2000-08-31 The Uab Research Foundation Taxane derivatives for targeted therapy of cancer
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
SG147286A1 (en) 1999-10-12 2008-11-28 Cell Therapeutics Inc Manufacture of polyglumate-therapeutic agent conjugates
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
CA2410887C (en) * 2000-06-02 2012-07-24 Bracco Research Usa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US8263739B2 (en) * 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
JP2002047298A (ja) 2000-07-10 2002-02-12 Academia Sinica 新規抗がん剤伝達系
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
AU2000265052A1 (en) 2000-07-31 2002-02-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
DE60141992D1 (no) * 2000-09-05 2010-06-10 Biosight Ltd
US7420030B2 (en) * 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
WO2002020822A2 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Biopanning and rapid analysis of selective interactive ligands (brasil)
WO2002087497A2 (en) 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
EP1401818A2 (en) * 2001-05-30 2004-03-31 Targesome, Inc. Targeted multivalent macromolecules
US7129261B2 (en) 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
PT1401863E (pt) * 2001-06-08 2009-07-23 Ipsen Pharma Análogos quiméricos da somatostatina-dopamina
US7893223B2 (en) * 2001-07-17 2011-02-22 Bracco Imaging S.P.A. Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
AU2002339863A1 (en) * 2001-08-31 2003-03-18 Abmaxis, Inc. Multivalent protein conjugate with multiple ligand-binding domains of receptors
CA2461099A1 (en) * 2001-09-21 2003-04-10 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
WO2003026577A2 (en) * 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US20030083241A1 (en) 2001-11-01 2003-05-01 Young Charles W. Use of somatostatin receptor agonists in the treatment of human disorders of sleep hypoxia and oxygen deprivation
WO2003057214A1 (en) 2001-12-28 2003-07-17 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
AU2003224644A1 (en) 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
CN102133407A (zh) * 2002-03-01 2011-07-27 图兰恩教育基金管理人 治疗剂或细胞毒性剂与生物活性肽的偶联物
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
EP2301587B1 (en) * 2002-03-01 2014-06-25 Dyax Corp. KDR and VEGF/KDR binding peptides and their use in diagnosis
WO2004093804A2 (en) 2003-04-18 2004-11-04 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
CN101791409A (zh) * 2003-04-22 2010-08-04 研究及应用科学协会股份有限公司 肽载体
TWI262192B (en) * 2003-07-01 2006-09-21 Univ Nat Taiwan Labeling peptide for nasopharyngeal carcinoma (NPC) cells
US8236762B2 (en) * 2006-10-20 2012-08-07 Ipsen Pharma S.A.S. Peptide-cytotoxic conjugates

Also Published As

Publication number Publication date
US20070093645A1 (en) 2007-04-26
AU2004232314B2 (en) 2007-11-22
IL171204A (en) 2013-01-31
AU2004232314A1 (en) 2004-11-04
SG173223A1 (en) 2011-08-29
JP2010265271A (ja) 2010-11-25
CN1777439A (zh) 2006-05-24
RU2361876C2 (ru) 2009-07-20
EP2161037A2 (en) 2010-03-10
CA2523197A1 (en) 2004-11-04
EP1624884A4 (en) 2009-08-05
JP4578470B2 (ja) 2010-11-10
NO20054494D0 (no) 2005-09-28
CA2523197C (en) 2016-05-24
EP1624884A2 (en) 2006-02-15
NZ564694A (en) 2009-11-27
EP2662087A1 (en) 2013-11-13
NZ576739A (en) 2011-01-28
MXPA05011233A (es) 2005-12-14
JP2006524256A (ja) 2006-10-26
US8709998B2 (en) 2014-04-29
EP2161037A3 (en) 2010-05-26
CN101791409A (zh) 2010-08-04
KR20060003047A (ko) 2006-01-09
KR100817232B1 (ko) 2008-03-27
WO2004093807A3 (en) 2005-08-04
KR20070108953A (ko) 2007-11-13
WO2004093807A2 (en) 2004-11-04
RU2005136221A (ru) 2006-05-27

Similar Documents

Publication Publication Date Title
NO20054494L (no) Peptidvektorer
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
ATE408601T1 (de) Fredericamycin-derivate
NO20054371L (no) Somatostatin-dopamin kimaere analoger
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
EA200802213A1 (ru) Способы лечения заболеваний крови
NZ542616A (en) P38 inhibitors and methods of use thereof
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
DK1420801T3 (da) Anvendelse af fucaner til behandling af adhæsioner, arthritis og psoreasis
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
CY1108808T1 (el) Ενωσεις μοτιλιδης
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
EA201170344A1 (ru) Азаиндольные ингибиторы iap
NO20072285L (no) S-mirtazapin for behandling av hetetokter
RS20060280A (en) Novel keto-oxadiazole derivatives as cathepsin inhibitors
EA200501310A1 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения боли

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application